查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1293804

腦膜炎球菌疫苗市場：按類型（組合疫苗、結合疫苗、男性B 疫苗）、按類別（肌內、皮下）、按劑量類型、按最終用戶、按目標群體-俄羅斯-烏克蘭衝突、高通貨膨脹- 2023-2030 年世界預報

Meningococcal Vaccines Market by Type (Combination Vaccines, Conjugate Vaccines, Men B Vaccines), Category (Intramuscular, Subcutaneous), Dosage Type, End User, Target Group - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2030年全球腦膜炎球菌疫苗市場將達到109.7272億美元，到2023年將大幅增長54.5378億美元，複合年增長率為10.24%。

FPNV定位矩陣

FPNV定位矩陣對於評估全球腦膜炎球菌疫苗市場至關重要。 通過檢查業務策略和產品滿意度等關鍵指標，它可以對供應商進行全面評估，使用戶能夠根據自己的特定需求做出明智的決策。 這種高級分析將供應商分為四個像限，並取得了不同程度的成功：前沿 (F)、探路者 (P)、利基 (N) 和重要 (V)。

市場份額分析

市場份額分析可以深入了解供應商在特定市場區域的當前狀態。 比較供應商對整體收入、客戶群和其他關鍵指標的貢獻，可以幫助公司更好地了解他們在爭奪市場份額時的表現以及面臨的情況。 該分析還揭示了特定行業的競爭程度、積累和分散的優勢以及研究基準年的合併特徵。

本報告提供了以下幾點見解：

1. 市場滲透率：提供有關主要公司所服務的市場的全面信息。

2. 市場開發：提供有關利潤豐厚的新興市場的詳細信息，並分析其在成熟市場領域的滲透率。

3. 市場多元化：提供有關新產品發布、未開發地區、最新開發和投資的詳細信息。

4. 市場趨勢：全面了解 COVID-19、俄羅斯-烏克蘭衝突和高通脹的累積影響。

5.競爭評估和信息：對主要公司的市場份額、戰略、產品、認證、監管狀況、專利狀況、製造能力進行綜合評估。

6. 產品開發和創新：提供對未來技術、研發活動和突破性產品開發的見解。

此報告回答了以下問題：

1. 腦膜炎球菌疫苗的全球市場規模和預測是多少？

2. 在預測期內，COVID-19 影響全球腦膜炎球菌疫苗市場的抑制因素和影響是什麼？

3.在預測期內，全球腦膜炎球菌疫苗市場應投資哪些產品/細分市場/應用/領域？

4. 腦膜炎球菌疫苗在全球市場的競爭策略是什麼？

5. 全球腦膜炎球菌疫苗市場的技術趨勢和監管框架是什麼？

6.全球腦膜炎球菌疫苗市場主要廠商的市場份額如何？

7. 腦膜炎球菌疫苗適合進入全球市場的形式和戰略舉措是什麼？

目錄

第一章前言

第二章研究方法

第 3 章執行摘要

第四章市場概述

第 5 章市場洞察

  • 市場動態
    • 驅動程序
      • 全球腦膜炎發病率上升
      • 增加研發活動和疫苗開發渠道
      • 加強免疫計劃和政府針對腦膜炎球菌病的努力
    • 抑制因素
      • 腦膜炎球菌疫苗生產成本高
    • 機會
      • 新興國家細菌性腦膜炎疫情及監測系統的完善
      • 加強協作和夥伴關係以支持疫苗開發
    • 作業
      • 與腦膜炎球菌疫苗相關的局限性和副作用
  • 市場趨勢
  • 新冠肺炎 (COVID-19) 的累積影響
  • 俄羅斯-烏克蘭衝突的累積影響
  • 高通脹的累積影響
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 監管框架
  • 客戶定制

第 6 章腦膜炎球菌疫苗市場：按類型

  • 聯合疫苗
    • 男子混合組
    • 梅尼特裡克斯
  • 結合疫苗
    • 梅納克特拉
    • 男士非洲背心
    • 腦膜炎科技
    • 門朱蓋特
    • 曼維奧
    • Niceback-C
    • 尼門裡克斯
    • NmVac4-DT
  • 男性 B 疫苗
    • 貝克塞洛
    • 托爾門巴
  • 多醣疫苗
    • 孟塞瓦克斯
    • 梅諾宗
    • NmVac4

第七章腦膜炎球菌疫苗市場：按類別

  • 肌肉注射
  • 皮下

第 8 章腦膜炎球菌疫苗市場（按劑量類型）

  • 額外疫苗接種
  • 初級疫苗接種

第 9 章腦膜炎球菌疫苗市場：按最終用戶劃分

  • 醫院藥房
  • 兒科診所
  • 零售藥店

第 10 章目標群體腦膜炎球菌疫苗市場

  • 成人使用
  • 青春期前
  • 青少年

第 11 章美洲腦膜炎球菌疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第12章亞太地區腦膜炎球菌疫苗市場

  • 澳大利亞
  • 中國
  • 印度
  • 印度尼西亞
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第13章歐洲、中東和非洲的腦膜炎球菌疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 意大利
  • 荷蘭
  • 尼日利亞
  • 挪威
  • 波蘭
  • 卡塔爾
  • 俄羅斯
  • 沙特阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合酋長國
  • 英國

第14章競爭態勢

  • FPNV定位矩陣
  • 市場份額分析：按主要公司劃分
  • 競爭情景分析：主要公司

第15章上市公司名單

第16章附錄

  • 討論指南
  • 關於許可證和價格
Product Code: MRR-430D42AA1024

The Global Meningococcal Vaccines Market is forecasted to grow significantly, with a projected USD 5,453.78 million in 2023 at a CAGR of 10.24% and expected to reach a staggering USD 10,972.72 million by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Meningococcal Vaccines Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Meningococcal Vaccines Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Type, market is studied across Combination Vaccines, Conjugate Vaccines, Men B Vaccines, and Polysaccharide Vaccines. The Combination Vaccines is further studied across MenHibrix and Menitorix. The Conjugate Vaccines is further studied across Menactra, MenAfriVac, Meningitec, Menjugate, Menveo, NeisVac-C, Nimenrix, and NmVac4-DT. The Men B Vaccines is further studied across Bexsero and Trumenba. The Polysaccharide Vaccines is further studied across Mencevax, Menomune, and NmVac4. The Men B Vaccines commanded largest market share of 43.91% in 2022, followed by Polysaccharide Vaccines.

Based on Category, market is studied across Intramuscular and Subcutaneous. The Intramuscular commanded largest market share of 67.06% in 2022, followed by Subcutaneous.

Based on Dosage Type, market is studied across Booster Vaccination and Primary Vaccination. The Primary Vaccination commanded largest market share of 68.18% in 2022, followed by Booster Vaccination.

Based on End User, market is studied across Hospital Pharmacies, Pediatric Clinic, and Retail Pharmacies. The Pediatric Clinic commanded largest market share of 42.32% in 2022, followed by Hospital Pharmacies.

Based on Target Group, market is studied across Adult, Preteen, and Teenager. The Preteen commanded largest market share of 68.03% in 2022, followed by Adult.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 37.99% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Meningococcal Vaccines Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Meningococcal Vaccines Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Meningococcal Vaccines Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Meningococcal Vaccines Market?

4. What is the competitive strategic window for opportunities in the Global Meningococcal Vaccines Market?

5. What are the technology trends and regulatory frameworks in the Global Meningococcal Vaccines Market?

6. What is the market share of the leading vendors in the Global Meningococcal Vaccines Market?

7. What modes and strategic moves are considered suitable for entering the Global Meningococcal Vaccines Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Meningococcal Vaccines Market, by Type, 2022 vs 2030
  • 4.3. Meningococcal Vaccines Market, by Category, 2022 vs 2030
  • 4.4. Meningococcal Vaccines Market, by Dosage Type, 2022 vs 2030
  • 4.5. Meningococcal Vaccines Market, by End User, 2022 vs 2030
  • 4.6. Meningococcal Vaccines Market, by Target Group, 2022 vs 2030
  • 4.7. Meningococcal Vaccines Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Incidence of Meningitis Across the World
      • 5.1.1.2. Rising R&D Activities and Vaccines Developments in the Pipeline
      • 5.1.1.3. Rising Immunization Programs and Government Initiatives for Meningococcal Diseases
    • 5.1.2. Restraints
      • 5.1.2.1. High Cost of Meningococcal Vaccines Production
    • 5.1.3. Opportunities
      • 5.1.3.1. Incidence of Bacterial Meningitis in Emerging Countries Coupled with Improvement in Surveillance System
      • 5.1.3.2. Elevation of Collaborations and Partnerships to Support the Development of the Vaccines
    • 5.1.4. Challenges
      • 5.1.4.1. Limitations and Side Effects Associated with Meningococcal Vaccines
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Meningococcal Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Combination Vaccines
    • 6.2.1. MenHibrix
    • 6.2.2. Menitorix
  • 6.3. Conjugate Vaccines
    • 6.3.1. Menactra
    • 6.3.2. MenAfriVac
    • 6.3.3. Meningitec
    • 6.3.4. Menjugate
    • 6.3.5. Menveo
    • 6.3.6. NeisVac-C
    • 6.3.7. Nimenrix
    • 6.3.8. NmVac4-DT
  • 6.4. Men B Vaccines
    • 6.4.1. Bexsero
    • 6.4.2. Trumenba
  • 6.5. Polysaccharide Vaccines
    • 6.5.1. Mencevax
    • 6.5.2. Menomune
    • 6.5.3. NmVac4

7. Meningococcal Vaccines Market, by Category

  • 7.1. Introduction
  • 7.2. Intramuscular
  • 7.3. Subcutaneous

8. Meningococcal Vaccines Market, by Dosage Type

  • 8.1. Introduction
  • 8.2. Booster Vaccination
  • 8.3. Primary Vaccination

9. Meningococcal Vaccines Market, by End User

  • 9.1. Introduction
  • 9.2. Hospital Pharmacies
  • 9.3. Pediatric Clinic
  • 9.4. Retail Pharmacies

10. Meningococcal Vaccines Market, by Target Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Preteen
  • 10.4. Teenager

11. Americas Meningococcal Vaccines Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Meningococcal Vaccines Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Meningococcal Vaccines Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. FPNV Positioning Matrix
  • 14.2. Market Share Analysis, By Key Player
  • 14.3. Competitive Scenario Analysis, By Key Player

15. List of Company Mentioned

16. Appendix

  • 16.1. Discussion Guide
  • 16.2. License & Pricing

1. Astellas Pharma Inc.

2. AstraZeneca PLC

3. Bavarian Nordic A/S

4. Bharat Biotech Ltd.

5. Bio-Manguinhos

6. Bio-Med (P) Limited

7. CanSino Biologics Inc.

8. Chongqing Zhifei Biological Products Co., Ltd.

9. Emergent BioSolutions Inc.

10. GlaxoSmithKline PLC

11. Incepta Pharmaceuticals Ltd.

12. Merck & Co., Inc.

13. Mitsubishi Tanabe Pharma Corporation

14. Nanolek, LLC

15. Novartis AG

16. Panacea Biotec Ltd.

17. Petrovax Pharm

18. Pfizer Inc.

19. Sanofi S.A.

20. Serum Institute of India Pvt. Ltd.

21. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

22. Sinovac Biotech Ltd.

23. Taj Pharmaceuticals Limited

24. Vabiotech

25. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. MENINGOCOCCAL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. MENINGOCOCCAL VACCINES MARKET SIZE, 2022 VS 2030
  • FIGURE 3. MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2022 VS 2030 (%)
  • FIGURE 5. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2030 (%)
  • FIGURE 6. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2022 VS 2030 (%)
  • FIGURE 7. MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2022 VS 2030 (%)
  • FIGURE 8. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2022 VS 2030 (%)
  • FIGURE 9. MENINGOCOCCAL VACCINES MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 10. MENINGOCOCCAL VACCINES MARKET DYNAMICS
  • FIGURE 11. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 15. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 20. MENINGOCOCCAL VACCINES MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 21. MENINGOCOCCAL VACCINES MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. MENINGOCOCCAL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. MENINGOCOCCAL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 6. MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENHIBRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENITORIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 10. MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENACTRA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENAFRIVAC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENINGITEC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENJUGATE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENVEO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. MENINGOCOCCAL VACCINES MARKET SIZE, BY NEISVAC-C, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. MENINGOCOCCAL VACCINES MARKET SIZE, BY NIMENRIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4-DT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 20. MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. MENINGOCOCCAL VACCINES MARKET SIZE, BY BEXSERO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. MENINGOCOCCAL VACCINES MARKET SIZE, BY TRUMENBA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 24. MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENCEVAX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. MENINGOCOCCAL VACCINES MARKET SIZE, BY MENOMUNE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. MENINGOCOCCAL VACCINES MARKET SIZE, BY NMVAC4, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 29. MENINGOCOCCAL VACCINES MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. MENINGOCOCCAL VACCINES MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. MENINGOCOCCAL VACCINES MARKET SIZE, BY BOOSTER VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. MENINGOCOCCAL VACCINES MARKET SIZE, BY PRIMARY VACCINATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 35. MENINGOCOCCAL VACCINES MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. MENINGOCOCCAL VACCINES MARKET SIZE, BY PEDIATRIC CLINIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. MENINGOCOCCAL VACCINES MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 39. MENINGOCOCCAL VACCINES MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. MENINGOCOCCAL VACCINES MARKET SIZE, BY PRETEEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. MENINGOCOCCAL VACCINES MARKET SIZE, BY TEENAGER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 70. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. MEXICO MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED STATES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 113. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 114. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 116. AUSTRALIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 121. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 122. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 123. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 125. CHINA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 129. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 130. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 131. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 132. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 137. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 138. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 139. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 140. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 141. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 146. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 147. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 148. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 149. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 155. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 156. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 157. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 162. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 164. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 165. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 171. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 173. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. THAILAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 215. VIETNAM MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 231. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 232. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 234. DENMARK MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 239. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 240. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 241. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 242. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. EGYPT MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 247. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 248. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 249. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 250. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 252. FINLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 255. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 256. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 257. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 258. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 259. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 260. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 261. FRANCE MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 264. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 265. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 266. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 267. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 268. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 270. GERMANY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 271. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 272. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 273. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 274. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 275. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 276. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 277. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. ISRAEL MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 280. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 281. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 282. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 283. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 284. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 285. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 286. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 287. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 288. ITALY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 289. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 290. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 291. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 292. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 293. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 294. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 295. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 296. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 297. NETHERLANDS MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 298. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 300. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 301. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 302. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 303. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 304. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 305. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. NIGERIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 307. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 308. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 309. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 310. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 311. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 312. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 313. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 315. NORWAY MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 316. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 317. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 318. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 319. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 320. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 321. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 322. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 324. POLAND MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 325. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 326. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 327. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 328. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY MEN B VACCINES, 2018-2030 (USD MILLION)
  • TABLE 329. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY POLYSACCHARIDE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 330. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY CATEGORY, 2018-2030 (USD MILLION)
  • TABLE 331. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY DOSAGE TYPE, 2018-2030 (USD MILLION)
  • TABLE 332. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 333. QATAR MENINGOCOCCAL VACCINES MARKET SIZE, BY TARGET GROUP, 2018-2030 (USD MILLION)
  • TABLE 334. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY COMBINATION VACCINES, 2018-2030 (USD MILLION)
  • TABLE 336. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, 2018-2030 (USD MILLION)
  • TABLE 337. RUSSIA MENINGOCOCCAL VACCINES MARKET SIZE